Immatics (IMTX) Other Non-Current Assets (2019 - 2025)
Immatics (IMTX) posted Other Non-Current Assets of $2.2 million for Q4 2025, up 124.64% sequentially from $958625.2 in Q3 2025, and up 61.22% YoY from $1.3 million in Q4 2024.
Immatics (IMTX) Other Non-Current Assets (2019 - 2025) Analysis & Trends
Immatics has reported Other Non-Current Assets for 7 years, with the latest figure at $2.2 million in Q4 2025.
- Quarterly Other Non-Current Assets rose 61.22% year-over-year to $2.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.2 million (up 61.22% YoY) and the FY2025 annual result came in at $2.1 million, up 54.49% from the prior year.
- Other Non-Current Assets improved to $2.2 million in Q4 2025 per IMTX's latest filing, from $958625.2 in the prior quarter.
- Over five years, Other Non-Current Assets peaked at $5.0 million in Q2 2022 and troughed at $710473.1 in Q1 2021.
- A 5-year average of $1.8 million and a median of $1.4 million in 2024 frame the typical range for Other Non-Current Assets.
- The sharpest annual moves came in 2022 and 2023: Other Non-Current Assets jumped 390.53% in 2022, then plunged 56.98% in 2023.
- Over 5 years, Other Non-Current Assets stood at $727565.5 in 2021, then surged by 256.88% to $2.6 million in 2022, then declined by 16.42% to $2.2 million in 2023, then sank by 38.45% to $1.3 million in 2024, then surged by 61.22% to $2.2 million in 2025.
- According to Business Quant data, Other Non-Current Assets over the past three periods registered $2.2 million, $958625.2, and $1.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 124.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 42.45 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 109.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 18,237.65 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 62.96 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 65.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 104.44 Mn |
| 10 | Immatics | 1.27 Bn | 719.31 Mn | - | 2.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.15 Mn |
| Sep 30, 2025 | 958,625.17 |
| Jun 30, 2025 | 1.13 Mn |
| Mar 31, 2025 | 1.19 Mn |
| Dec 31, 2024 | 1.34 Mn |
| Sep 30, 2024 | 1.32 Mn |
| Jun 30, 2024 | 1.44 Mn |
| Mar 31, 2024 | 1.49 Mn |
| Dec 31, 2023 | 2.17 Mn |
| Sep 30, 2023 | 1.81 Mn |
| Jun 30, 2023 | 2.15 Mn |
| Mar 31, 2023 | 2.43 Mn |
| Dec 31, 2022 | 2.60 Mn |
| Sep 30, 2022 | 4.05 Mn |
| Jun 30, 2022 | 4.99 Mn |
| Mar 31, 2022 | 986,534.85 |
| Dec 31, 2021 | 727,565.52 |
| Sep 30, 2021 | 847,907.58 |
| Jun 30, 2021 | 1.02 Mn |
| Mar 31, 2021 | 710,473.07 |